ImaRx Therapeutics, Inc. company was founded in 1999. ImaRx Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the development of therapies for stroke and other vascular disorders, using its microbubble technology. Its lead program, SonoLysis, involves the administration of its MRX-801 microspheres and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The MRX-801 microspheres are a proprietary formulation of a lipid shell encapsulating an inert biocompatible gas. Discontinued operations In September 2008, the company divested its urokinase business to Microbix.

Roche Scientific Company (India) is the Indian arm of Roche. Roche's products and services address the needs for prevention, diagnosis, and treatment of disease, and Roche Scientific Company (India) keeps the Indian product pipeline moving smoothly. The company, along with Roche Diagnostics (India), ensures Roche's products and services comply with Indian regulations including registration of new products, control of clinical trials, and monitoring of guidelines set by the International Federation of Pharmaceutical Manufacturers Association (IFPMA). The company also sponors research and development projects for new bulk drugs in India and disseminates product information via medical education programs.

Genentech, Inc. (Genentech) is a biotechnology company that discovers, develops, manufactures and commercializes pharmaceutical products to treat patients with unmet medical needs. It commercializes multiple biotechnology products and also receives royalties from companies that are licensed to market products based on the Company’s technology. Genentech commercializes various products in the United States, including Avastin, Rituxan, Herceptin, Lucentis, Xolair, Tarceva, Nutropin, Activase, TNKase, Cathflo Activase, Pulmozyme and Raptiva. The Company’s licensed products include Trastuzumab, Rituximab, Bevacizumab, Dornase alfa, recombinant, Alteplase and Tenecteplase, Somatropin, Daclizumab, Ranibizumab, Etanercept, Adalimumab and Infliximab. In March 2009, Roche Holding Ltd. completed the acquisition of Genentech.

UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and in the area of immunology on allergies, bone loss disorders, Crohn’s disease, rheumatoid arthritis and Systemic lupus erythematosus. UCB SA delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. UCB also has a selective presence in primary care. The Company, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States. As of December 31, 2008, UCB SA had a number of wholly owned subsidiaries in the United States, Canada, Europe, Asia, South America and Australia.

Third Wave Technologies is riding the biotech breakers. Using its Invader technology, Third Wave develops molecular diagnostic tests that detect genetic variations associated with a variety of conditions, including cystic fibrosis, cardiovascular risk factors, and infectious disease. Some tests can determine a patient's likely response to certain drugs, making it possible for doctors to avoid prescribing a drug that might cause dangerous side effects. Third Wave company has a strong presence in Japan, where it has a collaboration agreement with genetic researchers at the University of Tokyo. Third Wave Technologies was acquired by Hologic in 2008 for $580 million.

Allermed Laboratories, Inc. company was founded in 1971. Allermed Laboratories knows that in the case of allergies, a little bit of what caused the problem can be the solution. The company manufactures allergenic extracts, such as plant pollens, insects, fish and shellfish, and various foods, used to both diagnose and treat allergic conditions. The company is also developing additional skin tests for allergies, as well new tests to detect Leishmania parasite infections and exposure to the fungus Coccidioides immitis. Other products include empty test vials, vial trays, diluents, and extract mixing syringes. Outside of allergists' offices, the company provides environmental testing kits to detect mold contamination of buildings.

China Sky One Medical, Inc. is engaged in the development, manufacture, marketing and sale of over-the-counter, branded nutritional supplements and over-the-counter plant and herb based pharmaceutical and medicinal products. Its principal products are external use Traditional Chinese Herbal Remedies/Medicines (TCM). The Company is also an integrated manufacturer, marketer and distributor of external use Chinese medicine products sold primarily in China and through Chinese domestic pharmaceutical chains. The Company sells both its own manufactured products, as well as medicinal and pharmaceutical products manufactured by others in China. All of its business is conducted through its wholly owned subsidiary, American California Pharmaceutical Group, Inc. (ACPG) which, in turn, wholly owns Harbin Tian Di Ren Medical Science and Technology Company (TDR). On April 3, 2008, TDR completed its acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.

Osiris Therapeutics, Inc. company was founded in 1992 and is headquartered in Columbia, Maryland. Osiris Therapeutics, Inc., a stem cell therapeutic company, develops products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States. The company's principal product includes Prochymal, which is in phase III clinical trials for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, Crohn's disease, and acute radiation syndrome; and in phase II clinical trials for the treatment of Type I diabetes mellitus, acute myocardial infarction, and chronic obstructive pulmonary disease. Its product also consists of Chondrogen, a Phase II clinical trial product for the treatment of osteoarthritis and the reduction of pain in the knee. Osiris Therapeutics has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen; Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes; and JCR Pharmaceuticals Co., Ltd. for distributing Prochymal for the treatment of GvHD in Japan.

Herbalife Ltd. (Herbalife) is a global network marketing company that sells weight management, nutritional supplement, energy, sports and fitness products, and personal care products. Herbalife sells its products in 70 countries through a network of over 1.9 million independent distributors. The Company offers science-based products in four principal categories: weight management, targeted nutrition, energy, sports and fitness, and Outer Nutrition. In October 2008, Herbalife announced that it has begun doing business in Honduras, Nicaragua, and Guatemala. These countries become part of the Company's Mexico and Central America region. Five products from Herbalife's nutrition line will be available in each market, including the Company's flagship Formula 1 Nutritional Shake Mix, in four flavors; Performance Protein Powder; Herbal Aloe Drink Concentrate; NRG Tea, and Thermojetics Tea.

Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs for the treatment of drug addiction and obsessive-compulsive disorders. Its products include CPP-109, a chemical compound gamma-vinyl-GABA/vigabatrin, a Phase II clinical trial product for the treatment of cocaine addiction. The company also conducts a Phase II clinical trial of CPP-109 to evaluate its use in the treatment of methamphetamine addiction. In addition, it has a license agreement with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.